SEC Form 4 · accession 0001209191-18-009617
Viridian Therapeutics, Inc.\DE · VRDN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bruce Booth
Director
Period of report
Feb 13, 2018
Accepted (ET)
Feb 13, 2018 · 4:59 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001590750
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Feb 13, 2018 | P | 545,454 | $5.50 | A | 1,351,090 | I | See Footnote |
| Common StockF3 | holding | — | — | — | 3,142,580 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares purchased through the Issuer's follow-on public offering.
- F2The shares are held by Atlas Venture Fund X, L.P. ("Atlas Venture X"). Atlas Venture Associates X, L.P. ("AVA X LP"), is the general partner of Atlas Venture X, and Atlas Venture Associates X, LLC ("AVA X LLC"), is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture X, except to the extent of its pecuniary interest therein, if any.
- F3The shares are held by Atlas Venture Fund VII, L.P. ("Atlas Venture VII"). Atlas Venture Associates VII, L.P. ("AVA VII LP") is the general partner of Atlas Venture VII, and Atlas Venture Associates VII, Inc. ("AVA VII Inc.") is the general partner of AVA VII LP. Each of AVA VII LP and AVA VII Inc. disclaims Section 16 beneficial ownership of the securities held by Atlas Venture VII, except to the extent of its pecuniary interest therein, if any.